Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Periplakin is a structural protein encoded by the PPL gene in humans, classified as a member of the plakin family[5][2][3]. It is predominantly expressed in keratinocytes and incorporated into the cornified envelope, contributing to the protective barrier function of the epidermis[1][3][5]. The protein contains distinct domains: its N-terminal region interacts with the plasma membrane, the rod domain facilitates complex formation with envoplakin (another plakin family protein), and its C-terminus interacts with intermediate filaments, anchoring desmosomes to the cornified envelope[2][3][1]. Periplakin plays a key role in tissue structural integrity and is implicated as an autoantigen in paraneoplastic pemphigus, an autoimmune blistering disease[3]. It has limited tissue distribution but is essential for epidermal barrier formation and cellular architecture. There are currently no therapeutic agents directed at periplakin.
null
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Periplakin (PPL).